宿主靶向抗乙型肝炎病毒治疗策略研究新进展*

doi:10.3969/j.issn.1672-5069.2023.03.038

摘要/Abstract

摘要： 乙型肝炎病毒(HBV)感染是肝脏疾病进展甚至癌变的重要病因。HBV的完整生命周期依赖于宿主细胞,因此囊括了抑制病毒进入、破坏病毒核酸稳定性和增强宿主对HBV免疫反应等的靶向宿主细胞抗病毒(host-targeting antiviral,HTA)治疗方案颇有前景。本文综述了通过靶向作用于宿主和宿主因子,从而达到抗病毒作用的药物研发进展,以期为后续抗病毒研究和临床治疗提供选择手段。

关键词: 慢性乙型肝炎, 宿主靶向, 抗病毒治疗

Abstract: Chronic hepatitis B virus infection is an important factor in the progression of liver disease and hepatocellular carcinoma. The complete life cycle of hepatitis B virus is dependent on the host cell, which makes host-targeting antiviral (HTA) treatment options promising. The HTA includes inhibition of virus entry, destabilization of viral nucleic acids and enhancement of host immune response to HBV infection. This paper reviewed the development of medicines that target hosts and host factors in order to achieve the goal of hepatitis B virus suppression, with a view to providing a reference for subsequent antiviral research and clinical treatment.

Key words: Hepatitis B, Host-targeted antiviral treatment, Therapy

方慧晶, 朱传龙, 章莉莉. 宿主靶向抗乙型肝炎病毒治疗策略研究新进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 449-452.

Fang Huijing, Zhu Chuanlong, Zhang Lili. Perspective on host-targeted therapeutic antiviral strategies for patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2023, 26(3): 449-452.

参考文献

[1] Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.Gut,2015,64(12):1972-1984.
[2] Xia Y, Guo H. Hepatitis B virus cccDNA: formation, regulation and therapeutic potential.Antiviral Res,2020,180:104824.
[3] Lee HW, Lee JS, Ahn SH. Hepatitis B virus cure: targets and future therapies.Int J Mol Sci,2020,22(1):213.
[4] Wang J, Huang H, Liu Y, et al. HBV genome and life cycle.Adv Exp Med Biol,2020,1179:17-37.
[5] Bruss V, Hagelstein J, Gerhardt E, et al. Myristylation of the largesurface protein is required for hepatitis B virusin vitro infectivity.Virology,1996,218(2):396-399.
[6] König A, Döring B, Mohr C, et al. Kinetics of the bile acid transporter and hepatitis B virus receptor Na⁺/taurocholate cotransporting polypeptide (NTCP) in hepatocytes.J Hepatol,61(4):867-875.
[7] Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.J Hepatol,2016,65(3):490-498.
[8] Blank A, Eidam A, Haag M, et al. The NTCP-inhibitor myrcludex b: effects on bile acid disposition and tenofovir pharmacokinetics.Clin Pharmacol Ther,2018,103(2):341-348.
[9] Shimura S, Watashi K, Fukano K, et al. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.J Hepatol,2017,66(4):685-692.
[10] Fukano K, Oshima M, Tsukuda S, et al. NTCP oligomerization occurs downstream of the NTCP-EGFR interaction during hepatitis B virus internalization.J Virol,2021,95(24):e00938-21.
[11] Hu Q, Zhang F, Duan L, et al. E-cadherin plays a role in hepatitis B virus entry through affecting glycosylated sodium-taurocholate cotransporting polypeptide distribution.Front Cell Infect Microbio,2020,10:74.
[12] Appelman M D, Chakraborty A, Protzer U, et al. N-glycosylation of theNa⁺-taurocholate cotransporting polypeptide (NTCP) determines its trafficking and stability and is required for hepatitis B virus infection.PLoS One,2017,12(1):e0170419.
[13] Mueller H, Lopez A, Tropberger P, et al. PAPD5/7 are host factors that are required for hepatitis B virus RNA stabilization.Hepatology,2019,69(4):1398-1411.
[14] Sun L, Zhang F, Guo F, et al. The dihydroquinolizinone compound RG7834 inhibits the polyadenylase function of PAPD5 and PAPD7 and accelerates the degradation of matured hepatitis B virus surface protein mRNA.Antimicrob Agents Chemother,2020,65(1):e00640-20.
[15] Block TM, Young JAT, Javanbakht H, et al. Host RNA quality control as a hepatitis B antiviral target.Antiviral Res,2021,186:104972.
[16] Han X, Zhou C, Jiang M, et al. Discovery of RG7834: the first-in-class selective and orally available small molecule hepatitis B virus expression inhibitor with novel mechanism of action.J Med Chem,2018,61(23):10619-10634.
[17] Hwang N, Sun L, Noe D, et al. Hepatoselective dihydroquinolizinone bis-acids for HBsAg mRNA degradation.ACS Med Chem Lett,2021,12(7):1130-1136.
[18] Liu F, Lee ACH, Guo F, et al. Host poly(A) polymerases PAPD5 and PAPD7 provide two layers of protection that ensure the integrity and stability of hepatitis B virus RNA.J Virol,2021,95(18):e00574-21.
[19] Königer C, Wingert I, Marsmann M, et al. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses.Proc Natl Acad Sci U S A,2014,111(40):E4244-E4253.
[20] Tang L, Sheraz M, Mcgrane M, et al. DNA polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA.PLoS Pathog,2019,15(4):e1007742.
[21] Qi Y, Gao Z, Xu G, et al. DNA polymerase κ is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus.PLoS Pathog,2016,12(10):e1005893.
[22] Long Q, Yan R, Hu J, et al. The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation.PLoS Pathog,2017,13(12):e1006784.
[23] Kitamura K, Que L, Shimadu M, et al. Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus.PLoS Pathog,2018,14(6):e1007124.
[24] Yang H, Zhu XQ, Wang W, et al. The synthesis of furoquinolinedione and isoxazoloquinolinedione derivatives as selectivetyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.Bioorg Chem,2021,111:104881.
[25] Luo J, Luckenbaugh L, Hu H, et al. Involvement of host ATR-CHK1 pathway in hepatitis B virus covalently closed circular DNA formation.MBio,2020,11(1):e03423-419.
[26] Mohd-Ismail N K, Lim Z, Gunaratne J, et al. Mapping the interactions of HBV cccDNA with host factors.Int J Mol Sci,2019,20(17):4276.
[27] Decorsière A, Mueller H, Van Breugel P C, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor.Nature,2016,531(7594):386-389.
[28] Allweiss L, Giersch K, Pirosu A, et al. Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo.Gut,2022,71(2):372-381.
[29] Sekiba K, Otsuka M, Ohno M, et al. Pevonedistat, a neuronal precursor cell-expressed developmentally down-regulated protein 8–activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus.Hepatology,2019,69(5):1903-1915.
[30] Suslov A, Boldanova T, Wang X, et al. Hepatitis B virus does not interfere with innate immune responses in the human liver.Gastroenterology,2018,154(6):1778-1790.
[31] Chan Y K, Gack M U. Viral evasion of intracellular DNA and RNA sensing.Nat Rev Microbiol,2016,14(6):360-373.
[32] Lanford R E, Guerra B, Chavez D, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.Gastroenterology,2013,144(7):1508-1517.
[33] Menne S, Tumas DB, Liu KH, et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B.J Hepatol,2015,62(6):1237-1245.
[34] Tsai TY, Huang MT, Sung PS, et al. SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection.J Clin Invest,2021,131(11):e141965.
[35] Janssen HLA, Brunetto MR, Kim YJ, et al. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.J Hepatol,2018,68(3):431-440.
[36] Herschke F, Li C, Zhu R, et al. JNJ-64794964 (AL-034/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV/HBV mice via non-cytolytic mechanisms.Antiviral Res,2021:105196.
[37] Daffis S, Balsitis S, Chamberlain J, et al. Toll‐like receptor 8 agonist GS‐9688 induces sustained efficacy in the woodchuck model of chronic hepatitis B.Hepatology,2021,73(1):53-67.
[38] Amin OE, Colbeck EJ, Daffis S, et al. Therapeutic potential of TLR8 agonist GS‐9688 (selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators.Hepatology,2021,74(1):55-71.
[39] Mackman RL, Mish M, Chin G, et al. Discovery of GS-9688 (selgantolimod) as a potent and selective oral toll-like receptor 8 agonist for the treatment of chronic hepatitis B.J Med Chem,2020,63(18):10188-10203.
[40] Embrechts W, Herschke F, Pauwels F, et al. 2, 4-Diaminoquinazolines as dual toll-like receptor (TLR) 7/8 modulators for the treatment of hepatitis B virus.J Med Chem,2018,61(14):6236-6246.
[41] Ouaguia L, Dufeu‐Duchesne T, Leroy V, et al. Hepatitis B virus exploits C‐type lectin receptors to hijack cDC1s, cDC2s and pDCs.Clin Transl Immunol,2020,9(12):e1208.
[42] Sato S, Li K, Kameyama T, et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus.Immunity,2015,42(1):123-132.
[43] Korolowicz KE, Iyer RP, Czerwinski S, et al. Antiviral efficacy and host innate immunity associated with SB 9200 treatment in the woodchuck model of chronic hepatitis B.PLoS One,2016,11(8):e0161313.
[44] Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study.J Hepatol,2019,71(5):900-907.
[45] Ma H, Lim TH, Leerapun A, et al. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study.JHEP Rep,2021,3(6):100361.
[46] Wang W, Zhou X, Bian Y, et al. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B.Nat Nanotechnol,2020,15(5):406-416.
[47] Ma A, Motyka B, Gutfreund K, et al. A dendritic cell receptor-targeted chimeric immunotherapeutic protein (C-HBV) for the treatment of chronic hepatitis B.Hum Vaccin Immunother,2020,16(4):756-778.
[48] Spyrou E, Smith CI, Ghany MG. Hepatitis B: Current status of therapy and future therapies.Gastroenterol Clin North Am,2020,49(2):215-238.
[49] Bertoletti A, Tan AT. HBV as a target for CAR or TCR-T cell therapy.Curr Opin Immunol,2020,66:35-41.
[50] Zhang H, Wang F, Zhu X, et al. Antiviralactivity and pharmacokinetics of the hepatitis B virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection.Clin Infect Dis,2021,73(2):175-182.

宿主靶向抗乙型肝炎病毒治疗策略研究新进展^*

Perspective on host-targeted therapeutic antiviral strategies for patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陶贞贞, 王永莉, 孙红艳, 王慧芬. 二维剪切波弹性成像诊断慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 328-331.
[2]	赵景, 何秀波, 谌瑾寰. 肝脏剪切波弹性成像联合GGT/PLT比值诊断慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 332-335.
[3]	张丹蕾, 徐静. 艾米替诺福韦治疗慢性乙型肝炎患者早期疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 336-339.
[4]	郭晓玲, 张耀武, 李梦桃, 张辉. 恩替卡韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 340-343.
[5]	苏佩华, 宋枚芳, 赵彩彦. 慢性乙型肝炎合并非酒精性脂肪性肝病与肝细胞癌[J]. 实用肝脏病杂志, 2023, 26(3): 445-448.
[6]	尹雯, 鲁科翔, 王雪, 王彩艳. 恩替卡韦联合苦参素治疗HBeAg阳性慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 173-176.
[7]	魏丽, 刘博, 赵楠, 梁丽君. 恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 181-184.
[8]	张丹, 江建新. 重组细胞因子基因衍生蛋白与干扰素α-2b分别联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 27-30.
[9]	贾春锋, 高旋, 徐倩, 刘建华. 不同HBsAg水平的慢性乙型肝炎患者血清HIF-1α、ApoE和TGF-β1水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2023, 26(1): 140-141.
[10]	李向阳, 丁光伟, 靳铭. 恩替卡韦治疗慢性乙型肝炎合并NAFLD患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 776-779.
[11]	吴凤萍, 崔丹丹, 王怡恺, 李梅, 刘晨瑞, 南希, 贾晓黎, 党双锁. 血清BAFF预测聚乙二醇干扰素-α治疗非活动性HBsAg携带者临床治愈的效能分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 780-783.
[12]	齐孝安, 卢金喜, 袁林. 慢性乙型肝炎患者降钙素基因相关肽和α-干扰素-λ4基因多态性对α-干扰素治疗应答的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 784-787.
[13]	王玉珊, 孔银, 刘元元, 刘天府, 麻爱娣, 张亚萍, 李永芳, 张岭漪. 不同转换治疗策略对经治的低病毒血症慢性乙型肝炎患者疗效的影响:单中心回顾性研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 633-636.
[14]	徐欢, 谭钧元, 黄荷, 董丹丹. 聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及其外周血单个核细胞TLR4和B7-H1表达变化^*[J]. 实用肝脏病杂志, 2022, 25(5): 637-640.
[15]	王春莹, 屈耀宁, 乔炜, 刘静静, 胡颖辉. 恩替卡韦治疗慢性乙型肝炎患者血清HBV cccDNA和HBV pgRNA水平变化^*[J]. 实用肝脏病杂志, 2022, 25(5): 641-644.